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Review
Anti-nerve growth factor monoclonal 
antibodies for the control of pain in 
dogs and cats
Masataka Enomoto,1 Patrick W Mantyh,2 Joanna Murrell,3 John F Innes,4 B Duncan X Lascelles1,5,6,7
Nerve growth factor (NGF) is essential for the survival of sensory and sympathetic neurons during development. 
However, in the adult, NGF and its interaction with tropomyosin receptor kinase A receptor (TrkA) has been 
found to play a critical role in nociception and nervous system plasticity in pain conditions. Thus, various 
monoclonal antibody (mAb) therapies targeting this pathway have been investigated in the development of 
new pharmacotherapies for chronic pain. Although none of the mAbs against NGF are yet approved for use in 
humans, they look very promising for the effective control of pain. Recently, species-specific anti-NGF mAbs for 
the management of osteoarthritis (OA)-associated pain in dogs and cats has been developed, and early clinical 
trials have been conducted. Anti-NGF therapy looks to be both very effective and very promising as a novel 
therapy against chronic pain in dogs and cats. This review outlines the mechanism of action of NGF, the role of 
NGF in osteoarthritis, research in rodent OA models and the current status of the development of anti-NGF mAbs 
in humans. Furthermore, we describe and discuss the recent development of species-specific anti-NGF mAbs for 
the treatment of OA-associated pain in veterinary medicine.
Introduction
Osteoarthritis (OA) is a slowly progressive degenerative 
joint disease characterised by whole-joint structural 
changes including articular cartilage, synovium, 
subchondral bone and periarticular components, 
which can lead to pain and loss of joint function.1–4 
It is considered to primarily affect the hip, stifle and 
elbow joints in dogs,5 although no comprehensive, 
prospective studies of the prevalence of canine 
OA throughout the skeleton have been performed. 
Although most commonly initiated early in life by 
developmental disease (eg, hip dysplasia), many other 
factors play a role in its development, including diet, 
genetics, environment, obesity and age.4 6 7 In cats, hip, 
stifle, hock and elbow joints are the most commonly 
affected synovial joints.3 Although much less is 
known about the aetiology of OA in cats, idiopathic 
OA is considered common, with congenital, traumatic, 
infectious, nutritional and immune-mediated causes 
having been documented, similar to other species.3 
OA is a condition associated with clinical signs in a 
large percentage of the population, with an estimated 
minimum of 20 per cent to 30 per cent of dogs affected 
clinically and up to 40 per cent of all cats being affected 
clinically (90  per  cent of all cats over 12 years of 
age).3 5 8 The disease is currently incurable with negative 
consequences related to pain, mobility impairment 
and decreased quality of life.9 Pain results in both 
local and distant deterioration of the musculoskeletal 
system as a result of decreased and altered mobility. 
The pathological processes of OA, such as joint capsule 
thickening and fibrosis, contribute to altered range of 
motion that compounds the musculoskeletal changes. 
Additionally, the ongoing nociceptive input into the CNS 
results in somatosensory system changes and central 
sensitisation10 11, which contributes to the perception of 
pain. The combined effects of pain, central sensitisation 
and activity impairment may have negative effects on 
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the affective state, heightening anxiety, depression, 
sleep impairment12 and cognitive dysfunction as 
reported in humans.13 14 
Currently, pharmacological treatment of pain 
centres around non-steroidal anti-inflammatory drugs 
(NSAIDs). These are used to relieve pain and promote 
functional improvement.2 Globally, several NSAIDs 
are approved for use in dogs, but only two NSAIDs are 
approved for use long-term in cats and only in certain 
countries. Despite their widespread use and obvious 
benefit in many cases, NSAIDs are not always sufficiently 
effective when used as monotherapy.15 Additionally, 
there are safety and tolerability concerns with their 
use in both dogs and cats.16–19 Beyond cyclooxygenase-
inhibiting NSAIDs and the recently approved 
piprant NSAID, a prostaglandin receptor antagonist, 
grapiprant,20 treatment options for the control of pain 
are very limited. Furthermore, evidence for efficacy of 
so-called adjunctive analgesics is extremely limited15 21. 
Additionally, there are few proven non-drug therapies, 
and none that have been shown to provide rapid pain 
relief. Therefore, OA related-pain remains a challenging 
clinical entity to treat, and indeed, OA-associated pain 
is one of the most common reasons for euthanasia 
in dogs.22 23 Thus, there is an urgent need to develop 
effective treatments for OA-related pain in dogs and 
cats.
Advent of monoclonal antibodies
With greater understanding of pathogenesis of OA 
coupled with advances in biotechnology, specific 
immunomodulatory therapies called biological 
agents have been introduced for the treatment of joint 
diseases, specifically immune-mediated joint diseases. 
Biological agents are medical products that are isolated 
from a variety of natural sources (human, animal or 
microorganism). This is in contrast to most drugs that 
are chemically synthesised. Biological agents include 
a wide range of products such as vaccines, blood and 
blood components, gene therapy and recombinant 
therapeutic proteins. They also may be produced by 
biotechnology methods. In human medicine, biological 
products often offer the most effective means to treat 
a variety of medical illnesses and conditions. The 
monoclonal antibodies (mAbs) have proven to be 
extremely effective in a variety of diseases in humans. 
Monoclonal antibodies are produced from single 
B-lymphocyte clones in mice or through recombinant 
engineering. They are monovalent antibodies that 
specifically bind to target molecules including cytokines, 
receptors or cells.24 The binding results in blocking 
the activity of the target. They were first generated in 
mice in 1975 using a hybridoma technique25 involving 
immunising a certain species against a specific epitope 
on an antigen and obtaining B-lymphocytes from the 
animal’s lymphoid tissue. B-lymphocytes are then fused 
with an immortal myeloma cell, a type of B-cell tumour, 
and these hybridomas can be maintained in vitro and 
will continue to secrete antibodies with appropriate 
specificity. Administering purified non-human-derived 
antibodies to humans can cause immune reactions,26 and 
so antibody engineering technology has been developed 
to lower the risk of immune reactions.27 Engineering 
of antibodies by replacing mouse sequence-derived 
amino acids with human sequences has significantly 
reduced immunogenicity of this class of therapeutics.28 
Over the last 25 years, chimeric, humanised and fully 
human mAbs have been developed for use in humans 
Figure 1 Antibodies are large glycoproteins typically composed of two heavy chains and two light chains, each of which contain a variable domain (variable heavy (VH) 
or variable light (VL) and a constant domain (constant heavy (CH) or constant light (CL). The amino acid sequence of the variable domain varies greatly among 
antibodies and six ‘hyper-variable’ complementarity-determining region (CDR) loops within the variable domains give the antibody its specificity for binding to an 
antigen. In contrast, the constant domain is identical in all antibodies of the same isotype but differs in antibodies of different isotypes (IgA, IgD, IgE, IgG and IgM). The 
tail region of the constant domain (Fc region: CH2 and CH3) may direct immune effector functions by binding to cell receptors expressed on immune cells or initiating 
complementary-dependent cytotoxicity. Murine monoclonal antibodies (mAbs) are antibodies produced from individual cloned and immortalised mouse B cells. Most 
useful therapeutic antibodies have been constructed with the gamma immunoglobulin (IgG) isotype. Chimeric mAbs are antibodies made by fusing the genes encoding 
the variable region from a murine-derived mAb, with those from an immunoglobulin (Ig) constant region from a human antibody. Humanised mAbs retain only the CDRs 
(part of the variable domain from the original murine-derived mAb that binds to the specific antigen). Fully human mAbs have no murine sequences. Caninised and 
felinised mAbs are fully canine or feline specific. These can be made in several ways; for example, Nexvet have used a process of conversion based on alignment with 
immunoglobulin complementary DNA libraries (PETization).
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to decrease immunogenicity29 30 (figure  1). Chimeric 
mAbs are antibodies made by fusing the variable region 
from a murine-derived mAb, with the immunoglobulin 
(Ig) constant region from a human antibody.31 32 The 
resulting construct is approximately three quarters 
human.31 32 The next advance was the ‘humanization’ 
process.33 Initially, only the complementarity-
determining regions (CDRs) (part of the variable 
domain from the original murine-derived mAb that 
binds to the specific antigen) are retained, resulting in a 
construct that is approximately 95 per cent human.31 32 
Subsequently, fully human mAbs, which have no murine 
sequences, have been produced through transgenic 
mice and phage technologies.24 In general, the more 
humanised the construct is, the less immunogenic the 
mAb. However, the immunogenicity cannot be predicted 
based only on the amount of non-human sequence on 
the molecule. In fact, antidrug antibodies to even fully 
humanised mAbs have been reported due to factors 
such as aggregates and adjuvant-like contaminants, 
although these issues have largely been resolved by 
improvements in manufacturing and formulating 
practices.34 Moreover, other key factors that are relevant 
to the immunogenicity of a compound include route of 
administration (intravenous v subcutaneous), treatment 
paradigm (continuous v intermittent) and concurrent 
immunosuppressive therapy. In clinical practice, these 
factors have proven to be relevant considerations in 
the therapeutic use of mAbs.31 32 Immune responses to 
therapeutic mAbs are undesirable as they can neutralise 
the action of therapeutic mAbs, and hypersensitivity can 
result in morbidity and mortality.35 Importantly, some of 
the mAb immunogenicity appears to be idiotypic where 
patients who develop antibodies after treatment with 
1 chimeric mAb might not be expected to demonstrate 
equal reactivity to another chimeric mAb.31 32
There are multiple mechanisms by which mAbs 
produce their effect. These include blockade of ligand–
receptor interaction or signalling pathways; altering 
cell populations (by engaging effector functions 
including the complement-dependent cytotoxicity, 
antibody-dependent cellular cytotoxicity and antibody 
dependent phagocytosis or apoptosis).29
The activation and sensitisation of peripheral 
nociceptors by inflammatory and hyperalgesic mediators 
such as cytokines is recognised as one of the main 
peripheral mechanisms responsible for joint pain.36 In 
parallel with an increased understanding of the role of 
the cytokines, chemokines and neurotrophins in joint 
pathology and pain,36 there has been growing interest 
the use of mAb therapy to target these molecules.29 
Nerve growth factor (NGF) is one of the cytokines37 that 
has received significant attention as a key regulator 
involved in both inflammatory and neuropathic pain.38
This paper will review the role of NGF in the arthritic 
joint, efficacy of anti-NGF therapy based on murine 
OA models, the current status of the development of 
anti-NGF mAbs in humans and will also discuss the 
recent development of anti-NGF mAbs for the treatment 
of OA-associated pain in experimental and clinical 
studies in veterinary medicine.
Monoclonal antibodies targeting NGF
NGF and its pain pathway
NGF was originally discovered as a critical factor for 
the development and maintenance of sensory and 
sympathetic neurons in the developing nervous system 
(reveiwed in ref 39). In the prenatal and early postnatal 
periods, NGF is required for survival of both sensory 
and sympathetic neurons.40 41 However, in adults, 
the main role of NGF in the periphery shifts from 
trophic support of sensory and sympathetic neurons 
to modulation of nociceptive neuronal activity.39 
Preclinical and clinical research over the past several 
decades has clearly demonstrated the important role of 
NGF in nociceptor sensitisation in a wide variety of both 
acute and chronic pain states including postoperative 
and OA pain39 42–44 (figure 2). In this respect, NGF can 
be considered to be similar to prostaglandin E2 (PGE2), 
which also produces nociceptor sensitisation, and 
both play a role in the sensitisation of nerves following 
injury—the fundamental protective effect of pain. 
NGF is produced and released by peripheral tissues in 
response to noxious stimuli. It functions as a soluble 
signalling protein that mediates its activity via binding 
to two distinct cell surface receptors (NGFRs), the high-
affinity NGF-specific tropomyosin receptor kinase A 
(TrkA) and the low affinity p75 neurotrophin receptor 
(p75NTR). When NGF binds to TrkA expressed on the 
peripheral terminals of sensory nerve fibres, the NGF/
TrkA complex is internalised. The NGF/TrkA complex 
is retrogradely transported to the cell body of sensory 
neurons, located in the dorsal root ganglia (DRG). This 
modulates and/or increases the expression of a variety 
of cell surface receptors and ion channels involved in 
nociception including the transient receptor potential 
vanilloid 1, acid-sensing ion channels, bradykinin 
receptors, voltage-gated sodium channels, voltage-
gated calcium channels and mechanotransducers. 
This results in an increase the excitability of primary 
afferent fibres (peripheral sensitisation) through 
phenotypic alterations. NGF/TrkA signalling also leads 
to transcriptional changes that result in the increased 
expression of pronociceptive neurotransmitters such as 
substance P, calcitonin gene-related peptide (CGRP) and 
brain-derived neurotrophic factor. Thus, NGF induces 
functional, as well as phenotypic, alterations in the 
primary afferent fibre. In the periphery, NGF also binds 
to TrkA located on mast cells and other immune cells 
and elicits the release of inflammatory mediators such 
as histamine, serotonin and NGF itself. Thus, NGF can 
trigger peripheral sensitisation and sensitises adjacent 
nociceptive neurons as a result of the release of these 
inflammatory mediators.39 42–44 In conditions where NGF 
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is playing a pivotal role in the pronociceptive processes, 
an analgesic that blocks NGF/TrkA signalling may be 
useful.44 45
It should be noted that several reports suggest that 
NGF and TrkA expression in the CNS may contribute to 
driving chronic pain.46 47 The present review is focused 
on peripherally restricted anti-NGF mAb therapies that 
do not readily cross the blood–brain barrier (BBB). 
However, previous reports using a small molecule 
pan-Trk inhibitor (which readily crosses the BBB and 
binds to TrkA, B and C with nanomolar affinity) showed 
very similar efficacy as peripherally restricted anti-NGF 
mAb therapies in attenuating both non-malignant and 
malignant skeletal pain.39 48 49 Thus, while peripherally 
restricted anti-NGF therapies presumably blocks NGF 
induced sensitisation and sprouting of nociceptors,39 
it will be important to further define how NGF and 
TrkA in the CNS may also contribute to the induction 
and maintenance of chronic pain. Additionally, it will 
be important to define how anti-NGF therapies that are 
restricted to the periphery, such as mAbs, modulate 
centrally driven or maintained processes involved in 
chronic pain.
NGF and OA-associated pain and pathology
Evidence for a contribution of locally produced NGF 
to joint pathology, as well as pain in arthritic joints 
has emerged. NGF can induce joint pain via a direct 
sensitisation of nociceptors.50 Indeed, a single intra-
articular (IA) injection of NGF into normal rat knees 
produced dose-dependent, long-lasting increases in pain 
behaviours (asymmetrical gait and allodynia at a site 
distal to the injected joint), joint swelling and synovial 
macrophage infiltration.51 Other work has shown that 
in arthritic joints, NGF is released by damaged cells 
including synovial cells and chondrocytes, and elevated 
NGF and/or its receptors are detected in synovium and 
articular cartilage in murine models of OA.52 53 Similarly, 
elevated NGF levels are found in synovial fluid, 
synovium, osteochondral junction and articular 
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Figure 2 Schematic diagram of the involvement of nerve growth factor (NGF) in nociception and nervous system plasticity. In osteoarthritis (box 1), NGF is produced 
and released by peripheral tissues (such as chondrocytes) and can bind to its receptor, TrkA located on primary afferent (sensory) fibres. In addition, NGF that is 
released in the periphery also binds to TrkA located on mast cells and other immune cells and subsequently elicits the release of inflammatory mediators such as 
histamine, serotonin (5HT) and NGF itself (box 2). When NGF binds to TrkA, on TrkA-positive primary afferent nerve fibres, the NGF/TrkA complex is internalised 
and retrogradely transported to the cell body of the sensory neurons that are located in the DRG. This modulates and/or increases the expression of a variety of cell 
surface receptors and ion channels involved in nociception including TRPV1, ASIC, BR2, Nav, Cav, K and putative mechanotransducers, which result in an increase the 
excitability of primary afferent fibres (peripheral sensitisation) (box 3). NGF/TrkA signalling also leads to transcriptional changes that result in the increased expression 
of pronociceptive neurotransmitters such as SP, CGRP and BDNF. When these peptidergic (TrkA-positive) primary afferent neurons are subsequently stimulated, release 
of these peptides, in addition to glutamate acting on AMPA receptors, and binding to their respective receptors (SP to NK-1, CGRP to CGRP-R, BDNF to TrkB) may 
cause strong depolarisation of the postsynaptic second order projection neuron (box 4). This will result in the removal of the magnesium (Mg2+) block of the NMDA 
receptor, facilitating cellular windup. This increases the probability of central sensitisation and facilitated transmission through the dorsal horn synapse and then, via 
third-order neurons, to the sensory cortex in the brain. Thus, NGF is involved in the processes of inflammation in the periphery, and also in the sensitisation of primary 
afferent neurons through alteration of their functional phenotype. 5-HT, 5-hydroxytryptamine; AMPA, the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; 
ASIC, acid-sensing ion channel; BDNF, brain-derived neurotrophic factor; BR2, bradykinin receptor 2; Cav, voltage-gated calcium channel; CGRP, calcitonin gene-related 
peptide; CGRP-R, calcitonin gene-related peptide receptor; DRG, dorsal root ganglia; K, delayed-rectifier potassium channel; Nav, voltage-gated sodium channel; NMDA; 
the glutamatergic N-methyl-D-aspartate; NGF, nerve growth factor; NK-1, neurokinin 1 receptor; p75, neurotrophin receptor; SP, substance P; trkA, tropomyosin receptor 
kinase A; trkB, tropomyosin receptor kinase B; TRPV1, transient receptor potential vanilloid 1.
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cartilage in human patients with arthritis.54–58 A recent 
work has shown elevated levels of NGF in synovial fluid 
in dogs with naturally occurring OA compared with 
healthy joints.38 Interestingly, experimental studies have 
demonstrated that augmented NGF gene expression and 
NGF immunoreactivity in the joint correlates with pain-
related behavioural changes in surgically induced OA in 
mice.53 59 Administration of an anti-NGF/TrkA signalling 
molecule significantly decreased pain behaviours in a 
murine model of OA.59–63 The antinociceptive effect of 
anti-NGF antibody appeared to be equal to the highest 
tolerated dose of indomethacin, as assessed by a 
vocalization test in a complete Freud’s adjuvant (CFA) 
induced arthritic model in rats.60 In another study 
comparing the efficacy of different analgesics, Adams 
et al61 examined the ability of different analgesics 
(morphine, tramadol, NSAIDs and anti-NGF therapy) 
to attenuate gait impairment using a gait analysis 
system in the same arthritic model. They showed 
that intraperitoneal administration of anti-NGF mAb 
produced a profound improvement in gait parameters 
in a dose-dependent manner. Its effect was the same or 
greater than clinically efficacious doses of morphine 
and NSAIDs. Overall, basic science studies have shown 
a role of NGF in pain and pathology in OA and shown 
that anti-NGF therapies show robust analgesia that is 
equal to or greater than current analgesics.
Peripheral and central neuronal plasticity are key 
mechanisms in the development and maintenance of 
chronic pain64 and evidence points to NGF as being a 
major determinant of plasticity in both the peripheral 
and CNS. Small doses of exogenous NGF delivered 
to intact DRG or into the intrathecal space in rats 
triggered a persistent hyperalgesia, indicative of 
peripheral and central sensitisation, respectively.65 66 
A recent study reported the effect of anti-NGF therapy 
on peripheral and CNS plasticity and associated 
hyperalgesia.53 Behavioural tests showed significantly 
reduced OA-associated pain and hyperalgesia in mice 
injected with anti-NGF mAb compared with a saline 
injected control group, suggesting that anti-NGF 
therapy is a potentially effective analgesic treatment 
for both the peripheral and the central plasticity 
components of chronic pain. It is worth noting that 
reducing sensitisation by NGF signalling blockade is 
not anticipated to block normal, protective, nociceptive 
signalling unlike traditional analgesics such as 
opiates.67
One potential mechanism behind OA-associated pain 
is ectopic sprouting of sensory and sympathetic nerve 
fibres. With the progression of OA in humans, nerve 
sprouting along new blood vessels can be detected, both 
into structures that are normally not innervated (eg, 
non-calcified cartilage, the osteochondral junction and 
meniscus), as well as normally innervated structures (eg, 
synovium).53 56 57 68 69 NGF is considered to be one of the 
main factors inducing nerve sprouting and neuromas 
in response to tissue and/or nerve injury, and NGF may 
promote angiogenesis itself.39 56 Studies of tissue from 
human patients with OA and rheumatoid arthritis have 
showed that the NGF immunoreactivity in pathological 
joint tissue was significantly higher than normal joint 
tissues. These studies showed NGF immunoreactivity 
was associated with increased sensory nerve innervation 
and sprouting (CGRP positive neurons) in the synovium 
and at the osteochondral junction.56 57 Interestingly, data 
suggest NGF activity may be correlated with symptoms. 
Investigators compared tissue from human patients 
with similar macroscopic chondropathy, half of whom 
were symptomatic and half of whom were asymptomatic 
knee chondropathy patients.53 57 In these reports, 
the NGF immunoreactivity was significantly greater 
in the synovium from patients with symptomatic OA 
compared those with asymptomatic OA.53 57 Supporting 
this association between NGF immunoreactivity and 
symptoms, Kc et al53 reported that sensory nerve (protein 
gene product 9.5 positive neurons) fibre innervation 
was markedly increased in the synovium from patients 
with symptomatic OA, and this change was colocalised 
with augmented NGF immunoreactivity. This may 
suggest that upregulation of sensory neurons and 
associated NGF/TrkA signalling are better correlated 
with OA symptoms than are cartilage lesions. In 
an experimental study in mice, sensory (CGRP and 
neurofilament 200 positive neurons) and sympathetic 
nerve fibres (tyrosine hydroxylase positive neurons) in 
synovium and periosteum were significantly increased 
following the injection of CFA.70 In the same mouse 
model, administration of anti-NGF mAb significantly 
reduced the sprouting of these sensory and sympathetic 
nerve fibres in synovium in the OA joint and attenuated 
joint pain.71 There appears to be good evidence that NGF 
may be responsible for pathological nerve sprouting 
in arthritis, and that this, and the presence of NGF, 
correlates well with clinical signs of pain.
Although NGF is known to induce angiogenesis that 
could contribute to inflammation, the effects of anti-NGF 
therapy on experimentally induced synovitis are mixed. 
One study reported anti-NGF therapy significantly 
decreased synovitis and cellular infiltration,62 while 
other studies have concluded that anti-NGF therapy 
did not alter synovitis and cellular infiltration.63 71 72 In 
clinical orthopaedics in humans and veterinary species, 
there is ongoing debate as to whether OA pain treatments 
should have anti-inflammatory effects to be optimally 
effective.
As cartilage damage progresses in rodent models of 
OA, gene expression and immunoreactivity of NGF in 
articular cartilage are increased.53 73 Similarly, in human 
patients, immunoreactivity of NGF and its receptors in 
articular cartilage and chondrocytes are elevated with 
severity of cartilage damage.53 58 Recently, an in vitro 
study suggested that NGF signalling is a contributing 
factor in articular cartilage degeneration in OA. In this 
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study, human cartilage tissue explants were harvested 
from early OA joints and cultured in serum-free medium 
with or without NGF for 14 days. NGF treatment 
resulted in extracellular matrix catabolism indicated 
by increased sulfated glycosaminoglycan release and 
matrix metalloproteinase (MMP) levels and activity.58 
Additionally, treatment with NGF neutralising antibody 
inhibited increased MMP levels and enhanced the 
level of tissue inhibitor of matrix metalloprotease-1 
in OA cartilage explants. However, the severity of 
cartilage damage in rats administered anti-NGF mAb 
was the same as those given saline control in a sodium 
monoiodoacetate (MIA) model of OA.63 72 Overall, 
at present, it is unclear if anti-NGF therapy has any 
potential protective effect on articular cartilage.
Thus, given the role of NGF in nociception and 
contribution to OA disease progression, various ways of 
preventing activation of NGF/TrkA have been developed, 
including capturing free NGF, preventing NGF binding 
to TrkA or inhibition of TrkA function.39 42–44 Methods for 
capturing free NGF and inhibition of TrkA function have 
been advanced into clinical trials in humans.
Potential beneficial effects of NGF
This review focuses on the treatment of pain via 
inhibition of NGF. However, there are potential beneficial 
effects of NGF. NGF is essential for the development and 
phenotypic maintenance of neurons in the peripheral 
nervous system (PNS) and for the functional integrity of 
cholinergic neurons in the CNS.74 In the PNS, in addition 
to the role in the regulation of neurotransmitters and 
neuropeptides synthesis, NGF has the protective action 
on the survival of degenerating peripheral nerve cells.39 
Deprivation of NGF can lead to damage of neurons, while 
exogenous NGF administration can promote peripheral 
nerve growth and re-establish functional activity.74 
Thus, NGF attracted clinicians for the potential clinical 
application to neurodegenerative diseases. However, 
the phase III clinical trials did not show positive results 
after administration of human recombinant NGF. 
Additionally, undesired adverse events (AEs), such as 
the peripheral pain, were observed.75 Clinical trials 
were halted.74 A specific role of NGF has been proposed 
for the cholinergic neuron population of the CNS.76 
NGF contributes to the maintenance of cell morphology 
and physiology of cholinergic neurons, which are 
highly dependent on NGF during both development 
and adulthood.77 Studies demonstrated that NGF was 
able to promote survival of basal forebrain cholinergic 
neurons, known to degenerate in age-related disorders 
(such as in Alzheimer’s disease (AD)).78 This leads to 
the hypothesis that intracerebral administration of NGF 
might reduce or prevent brain neuronal degeneration 
of patients with AD. However, clinical studies were 
stopped due to only mild neurological improvements 
and AEs, including systemic pain.79 In more recent 
years, other strategies have been applied for the 
delivery of NGF into the damaged brain neurons and to 
bypass safely the BBB (eg, nose-to-brain).74 NGF may 
affect a variety of CNS neurons, other than cholinergic 
origin, including the visual system.80 NGF and TrkA 
are expressed by many tissues in the eye.81 Topically 
applied NGF eye drops can reach the retina and the 
optic nerve,82 and there is interest in topically applied 
NGF for neurodegenerative diseases, such as glaucoma 
and neurotrophic keratitis.83 Moreover, eye NGF topical 
administration enhanced tear release in humans 
and bulldogs suffering of dry eye.74 Of note in these 
discussions is the fact that anti-NGF mAbs are confined 
to the periphery because of the BBB.
Recent data have suggested that NGF is a pleiotropic 
factor and its actions extend beyond the nervous 
system.76 NGF is produced and used by several cell types 
including structural (eg, epithelial cells and endotherial 
cells), accessory (eg, glial cells and astrocytes) and 
immune cells (eg, lymphocytes and mast cells).74 During 
the last two decades, evidence has been accumulated 
supporting the hypothesis that NGF possesses potential 
therapeutic properties on tissue healing (cutaneous 
and corneal ulcers), cardiomyopathy, and myocardial 
ischaemia.74
Development of anti-NGF therapy for humans
Although none of the mAbs against NGF are yet 
approved for use in humans, anti-NGF mAbs are in 
development as treatments for several pain conditions. 
Currently, three drugs that capture free NGF have been 
developed: tanezumab (humanised mAb; Pfizer, in 
collaboration with Eli Lilly), fulranumab (fully human 
mAb; Amgen) and fasinumab (fully human mAb; 
Regeneron Pharmaceuticals, in collaboration with 
Sanofi). In studies performed thus far, they have been 
administered intravenously or subcutaneously every 
four weeks to eight weeks and have demonstrated dose-
dependent efficacy in human patients with moderate to 
severe pain associated with symptomatic knee or hip 
OA.84–86 In a study in human patients with knee or hip 
OA, tanezumab reduced OA pain and improved function 
more than that observed with NSAIDs or opiates.87 The 
most common AEs observed across the clinical trials 
performed so far were peripheral oedema, arthralgia, 
extremity pain and neurosensory symptoms (primarily 
paraesthesia, hypoesthesia and hyperaesthesia).43 
However, overall, the AE rate has been small (1  per 
cent to 10 per cent in most studies), and anti-NGF mAb 
therapy has been generally well tolerated by the human 
patients.43 88–91 Abnormal sensory symptoms tended 
to occur within a short time after the first dose and 
were generally transient but tended to develop more 
frequently with higher doses of anti-NGF mAbs.43 84 
Overall, symptoms were generally considered mild to 
moderate in severity and did not generally result in early 
exit from the study.43 Furthermore, most symptoms 
were transient and resolved without permanent 
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sequelae within one month.43 Thus, based on work 
in rodent models and human clinical trials, anti-NGF 
mAb therapy looks promising for the effective control 
of OA pain. However, the development programmes for 
anti-NGF mAbs were temporary put on clinical hold 
by the Food and Drug Administration (FDA) due to an 
increased incidence of serious joint-related AEs from 
2010 to 2012. The incidence of serious joint-related 
AEs were initially postulated to be osteonecrosis and/
or rapidly progressive OA (RPOA) in the hip, knee and 
shoulder joints, which lead to early than expected joint 
replacement. These AEs were reported in 83 patients 
who had either received tanezumab monotherapy or 
tanezumab and NSAIDs. The incidence rate was 9 and 
23.9 per 1000 patient-years (the sum of events divided 
by the duration of administration of tanezumab), 
respectively. These AEs occurred during phase II and 
III trials in the tanezumab development programme 
where the mean duration of treatment was 199 days.92 
The incidence of joint destruction was higher in the 
patients with longer exposure of anti-NGF mAbs, 
larger doses of anti-NGF mAbs and concurrent use of 
NSAIDs.42 92 However, serious joint-related AEs were 
observed in some patients following a single treatment 
of anti-NGF mAb.91 Several cases occurred in multiple 
joints and also in non-index joints.92 Following extensive 
adjudication of these AEs,92 less than 1 per cent of the 
AEs were deemed to be due to osteonecrosis and the 
majority classified as RPOA. Characteristics of RPOA 
are rapid clinical deterioration (increase in pain) and 
radiographic progression of joint degeneration.93 The 
cause of these cases of RPOA is not currently understood 
and experimental studies found no evidence of a 
direct adverse effect on bone healing or joint health 
(bone, cartilage, joint vasculature or joint innervation) 
in animals (rodents) treated with anti-NGF mAbs at 
large multiples of the clinical exposure.94 95 In human 
medicine, the most prominent concern around anti-NGF 
revolves around RPOA. Although theories have been 
proposed, the cause of anti-NGF related RPOA remains 
unclear.96 Overloading, resulting from increased activity 
and weight-bearing due to good analgesia (analgesic 
arthropathy), immune reactions and neuropathic 
arthropathy (nerve damage resulting in loss of ability to 
feel the joint and decreases in joint stability) have been 
suggested as potential factors leading to RPOA following 
anti-NGF therapy.91 97 98 The increased incidence of 
RPOA associated with concurrent NSAID use is not 
understood, but it is possible that NSAIDs contribute 
to RPOA through prostaglandin-dependent and 
prostaglandin-independent mechanisms, including 
increasing the risk of microvascular thrombotic events 
in bone and inhibiting the repair of subchondral 
microfractures.91 However, this is speculative at the 
moment. To the authors’ best knowledge, the influence 
of coadministration of anti-NGF therapy and NSAIDs 
on joint health has not yet been evaluated in basic 
studies, and the reason for the increased incidence 
of RPOA associated with concurrent use of anti-NGF 
mAb and NSAIDs has not been elucidated. It appears 
the recommendation will be to avoid use of NSAIDs 
concurrently with anti-NGF therapy (see below). 
Another concern with using anti-NGF mAb was whether 
this therapy could cause loss of sensory or sympathetic 
nerve fibres in the adult as NGF itself is known to be 
required for the normal development of sensory and 
sympathetic nerve fibres in developing animals and 
humans. Experiments in both mice and monkeys showed 
that anti-NGF therapy did not induce loss of sensory or 
sympathetic nerve fibres in the skin or bone nor any sign 
of injury or degeneration in the cell bodies of sensory 
neurons in the DRG.94 99 100 Interestingly a partial FDA 
clinical hold was placed on all anti-NGF programmes 
from 2012 to 2015 due to anatomical changes in the 
cell bodies of postganglionic neurons, which was 
based on an observed reduction in size and neuronal 
count of primates receiving very high doses of anti-NGF 
therapy. However, subsequent detailed   toxicology 
studies in monkeys did not demonstrate any reduction 
in sympathetic function or neuronal cell counts.89 101 
While it did appear that primates exposed to high and 
prolonged doses of anti-NGF did have a reduced size 
of postganglionic sympathetic cell bodies, this change 
in cell body size returned to normal upon cessation of 
anti-NGF administration.100 In light of these data, a risk 
minimisation plan has been incorporated subsequent 
anti-NGF human studies by excluding patients with 
ongoing disorders of the sympathetic nervous system.100
After reviewing the data, the FDA advisory committee 
concluded that these serious joint AEs were probably 
related to the anti-NGF treatment. However, clinical 
trials for the development of anti-NGF mAbs in human 
have been restarted in 2015 with the adoption of a risk 
mitigation strategy, which included monitoring patient 
overuse of the skeletal using accelerometers, dosing 
restrictions and a recommendation against concomitant 
NSAID use in patients with OA. The decision by the FDA 
to allow the continued development of the drug class 
was made due to the potential significant benefit of 
anti-NGF therapy for a multitude of pain conditions 
and the absence of any direct link between the 
administration of anti-NGF mAbs and joint destruction. 
Indeed, in 2017, tanezumab received FDA fast track 
designation, recognising the significant potential 
benefit from this therapeutic. A recent search of the 
National Institutes of Health web site ( ClinicalTrials. 
gov) revealed that tanezumab is currently in phase III 
studies in the patients with OA of the hip and knee and 
chronic lower back pain with the bone cancer pain trials 
being conducted outside the USA.90
Glenmark Pharmaceuticals Ltd. has developed a 
TrkA antagonist (GBR 900) with the target indication 
being the treatment of chronic pain. This antibody has 
completed phase  I enabling preclinical development 
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programme102 and a phase I trial in normal volunteers 
( ClinicalTrials. gov identifier: NCT02235727). In the 
Good laboratory practice (GLP) toxicity studies, no 
dose-limiting toxicities were detected with GBR 900, 
even at high doses. This potentially differentiates 
GBR 900 from anti-NGF antibodies that do show 
preclinical toxicity. Reportedly, preclinical head-to-
head comparisons with anti-NGF antibodies in animal 
models of inflammatory pain demonstrated that GBR 
900’s efficacy profile compares favourably with that 
of anti-NGF antibodies.102 Another TrkA inhibitor 
(GZ389988) has been developed by Sanofi, formulated 
for IA administration to control OA pain. In the rat MIA 
model, a single IA injection of GZ389988 resulted in 
more normal weight-bearing for four weeks without 
any significant histopathological changes in joint 
tissues compared with placebo.103 Interestingly, IA 
injection into the contralateral joint had no effect on the 
ipsilateral limb joint pain, suggesting that IA injection 
does not result in substantial systemic exposure, which 
may limit the risk of AEs. A proof-of-concept study to 
assess the efficacy, tolerability and safety of GZ389988 
in human patients with painful OA of the knee has 
recently completed, but results are not yet available 
( ClinicalTrials. gov identifier: NCT02845271).
Development of anti-NGF mAbs for the dog and cat
Canine and feline NGF are closely homogenous to NGF 
in other species, such as human and mice. However, as 
mAbs from one species often can induce an immune 
response when used without modification in another 
species, for therapeutic purposes, antibodies need to be 
species specific to reduce the risk of immunoreactions 
to the antibody. It is likely that several companies 
have developed or are developing technology to 
create species-specific antibodies for the veterinary 
market (as evidenced by the recent approval of Zoetis’ 
interleukin  (IL)-31 mAB (https://www. zoetisus. com/ 
products/ dogs/ cytopoint/)), but in the pain arena, 
the only publicly available information at the time of 
writing this review was for the company Nexvet, which 
was recently purchased by Zoetis (http:// news. zoetis. 
com/ press- release/ investors/ zoetis- acquire- nexvet- 
biopharma- innovator- monoclonal- antibody- therapies- 
comp). Nexvet developed technology to create anti-NGF 
mAbs specifically for canine and feline use. In this 
approach, complementary DNA libraries are used to 
compare the natural variations in the sequences of 
the heavy and light chain of the mAb between donor 
species (human or rodent) and target species. This 
comparison enables the determination of the minimal 
number of changes at each position in the amino acid 
sequences that are required to convert the donor mAb 
variable region heavy and light chain sequences into 
mAb sequences containing only amino acids identified 
within target species. At sites where amino acid changes 
are necessary, the most similar amino acid in the matrix 
of the target species is substituted.
This results in 100  per  cent species-specific mAb 
sequences that carry a lower risk of rejection due to 
immunoreaction, while preserving high affinity and 
potent bioactivity. Nexvet successfully converted the 
rat anti-NGF mAb (αD11) into caninised and felinised 
anti-NGF mAbs with the goal of managing pain states, 
including OA.
Development of anti-NGF therapy for canine OA
Early work with Nexvet’s fully caninised anti-NGF mAb 
(ranevetmab) indicated a favourable PK profile (mean 
tissue distribution phase half-life of approximately 
12 hours and a mean plasma half-life time of nine days) 
and no evidence of an acute neutralising immunogenic 
response in dogs.104 In the kaolin injection pain model 
in dogs, efficacy was seen (reduced lameness).104 
Currently, there are two published clinical trials that 
evaluate the efficacy of single intravenous injection of 
ranevetmab (0.2 mg/kg).105 106 Both studies required 
a two-week withdrawal period of NSAIDs prior to the 
study starting, and NSAIDs were not permitted to be 
used throughout the study period, in order to best assess 
efficacy of the anti-NGF therapy. In a randomised and 
double-blind study where all dogs received ranevetmab, 
the safety and clinical effect was examined using an 
owner completed questionnaire—the Canine Brief Pain 
Inventory (CBPI) score.105 Nine dogs with OA received a 
single injection of ranevetmab during the 10 weeks of 
study period (either at the start, two or four weeks into 
the study), with owners blinded to the time of injection. 
They were evaluated every two weeks for six weeks 
following injection. At other evaluation times, the dogs 
received sterile saline, and the owners were unaware 
of the evaluation time at which the mAb had been 
administered. This study showed that significantly 
lower CBPI scores were seen compared with baseline 
scores until four weeks after treatment, and although 
values were not statistically significant, CBPI scores 
at six weeks after administration were still lower than 
baseline scores. In another randomised, double-blind, 
placebo-controlled pilot study,106 26 dogs suffering 
from OA pain were allocated to placebo or treatment 
group based on predominant site of problem (fore 
or hind limb impairment) and CBPI score. The dogs 
were assessed every two weeks for four weeks using 
objective accelerometry (which measures activity 
and movement) and subjective, owner-completed 
clinical metrology instruments (CMIs, CBPI, Client-
Specific Outcome Measures (CSOM) and Liverpool 
Osteoarthritis in Dogs) for the evaluation of efficacy. 
The dogs that received ranevetmab had significant 
improvement in all three CMIs compared with baseline 
scores throughout the study period and significantly 
greater activity compared with placebo group during 
the daytime period (09.00–17.00). Additionally, the 
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distribution of success/failure rates for the CBPI and 
CSOM was very similar to previous studies using 
carprofen and grapiprant.20 107 In both clinical studies, 
no AEs associated with treatment were reported. 
Finally, although the data have not been published yet, 
a pivotal, multicentre, placebo-controlled, randomised, 
double blind study was conducted at 12 sites (http:// 
ir. nexvet. com/ phoenix. zhtml? c= 253841& p= irol- 
newsArticle& ID= 2176442: this was announced on the 
website, but it is no longer active). Two hundred and 
sixty-two dogs with OA were enrolled in this study and 
allocated to treatment or placebo on a 2:1 ratio. They 
received ranevetmab subcutaneously once per month 
for three months. The efficacy and safety of the drug were 
evaluated using CMIs (CBPI and CSOM) over 84 days. 
Subcutaneous administration of ranevetmab appeared 
to result in a statistically significant improvement 
on the assessed level of pain as measured using CBPI 
improvement success/fail criteria as well as using 
CSOM improvement success/fail criteria. Furthermore, 
subjective veterinarian assessment of limb function and 
joint pain were also numerically superior to placebo for 
each composite variable at most evaluation points and 
included a statistically significant overall treatment 
effect for lameness, particularly relevant given the 
large placebo effect seen in veterinarian lameness 
assessments.108
Basic science studies have evaluated the IA route 
of administration, but as yet, there are no reports of 
studies looking at IA injection in the dog. Although there 
are no other publications on anti-NGF mAbs and dogs, 
a recent search revealed that Zoetis LLC109 and Abbott 
Laboratories110 as well as Nexvet Biopharma111–114hold 
patents for anti-NGF mAb in dogs.
Development of anti-NGF therapy for feline OA
Currently, to our knowledge, Abbott Laboratories110 and 
Nexvet Biopharma115 hold a patent for anti-NGF mAbs 
in cats. However, the only published data in cats are for 
the Nexvet feline anti-NGF mAb.
Initial pharmacokinetic and efficacy evaluation 
of frunevetmab, Nexvet’s fully felinised anti-NGF 
mAb, were performed by investigators using eight 
cats administered four different doses (from  2.0 mg/
kg to 28 mg/kg) subcutaneously with plasma 
concentrations measured over a 42-day period 
following injection.116 Frunevetmab had a peak 
plasma concentration of approximately three days 
and a mean plasma half-life time of nine days. It was 
well tolerated at dosages up to 28 mg/kg. In placebo-
controlled, unblinded work, using the kaolin injection 
pain model of cats showed that a single dose of 2 mg/
kg significantly decreased subjective lameness scores 
compared with placebo treatment.116 No AEs were 
seen. A single clinical trial has been published.117 
This was a blinded, placebo-controlled pilot study 
conducted in 34 cats with OA-associated pain to 
assess the efficacy of a single dose of frunevetmab 
(0.4 mg/kg or 0.8 mg/kg, subcutaneously) over a 
nine-week period. A two-week wash-out period 
from NSAIDs was required prior to the study, and 
cats were not permitted to be on NSAIDs during the 
study period. Outcome measures were objectively 
measured using collar-mounted accelerometers 
and CMIs.117 Objective accelerometry revealed a 
significant increase in activity compared with placebo 
treatment from two weeks to six weeks after injection. 
Furthermore, the mean activity increase over placebo 
over first three weeks after treatment (12.9  per 
cent) was greater than the increase over placebo 
produced by daily administration of 0.035 mg/kg of 
meloxicam (5.97  per cent) over a three-week period 
in an earlier study.118 Subjective owner assessments 
showed a significant effect of treatment over the first 
three weeks after administration, the first time in the 
published literature that owners have been able to 
correctly distinguish between treatment and placebo 
in cats with OA-associated pain under a parallel 
design, placebo-controlled study. This is particularly 
noteworthy given the very high caregiver placebo effect 
seen in feline chronic pain studies.119 The anti-NGF 
mAb was well tolerated, with a single injection of 
frunevetmab producing positive treatment effects 
with a duration of up to six weeks. Although the data 
have not been published yet, multicentre, placebo-
controlled, randomised, double-blind pilot field study 
that enrolled 126 cats with OA was conducted over 
three months to examine the efficacy of intravenous 
and subcutaneous monthly administration of 
frunevetmab (http:// ir. nexvet. com/ phoenix. zhtml? c= 
253841& p= irol- newsArticle& ID= 2176442: this was 
announced on the website, but it is no longer active). 
It appeared that both routes of administration were 
effective and, when they were combined for analysis, 
frunevetmab demonstrated statistically significant 
efficacy over placebo at multiple time points using 
CMIs (CSOM and Feline Musculoskeletal Pain Index). 
No significant adverse safety signals were observed 
in this study. In December 2016, Nexvet announced 
initiation of pivotal efficacy study of frunevetmab in 
cats: a placebo-controlled, randomised, double blind 
study with a target enrolment of 250 cats with OA 
at approximately 20 clinical sites around the USA. 
Enrolled cats will be randomly assigned to receive 
frunevetmab or placebo at a 2:1 ratio. Each cat will 
receive three doses, with each dose given 28 days 
apart. There are no updates on this at the time of 
publication.
Generally, anti-NGF mAb exposure is limited to 
peripheral tissues, because mAbs do not cross the 
BBB,120 although recent work has been performed 
developing techniques to allow mAbs to cross the 
BBB.121 However, anti-NGF mAbs can pass through 
the placental blood barrier and also be excreted in 
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milk,122 and their use should be avoided in pregnant or 
lactating animals. Anti-NGF mAbs from the maternal 
circulation cause fetal abnormalities in rodents, and in 
pregnant non-human primates, they caused increased 
rates of stillbirth, and increased postpartum infant 
mortality and morbidity, decreased infant growth, 
sensory and sympathetic nerve system changes and 
decreased infant primary antibody responses.123
Current limitations of our knowledge of anti-NGF therapy 
for canine and feline OA
Overall, in both dogs and cats, significant improvement 
has been seen in both subjective and objective 
(activity) measures following administration of 
anti-NGF mAbs, suggesting a positive analgesic effect 
of the same magnitude or greater than that expected 
with NSAIDs. However, the current assessment of 
the response to anti-NGF mAbs has not included gait 
analysis, which was the mainstay of assessment of 
NSAIDs until recently. Gait analysis is most suited to 
dogs with asymmetrical gait, and the dogs recruited to 
the studies performed thus far had multiple joint OA, 
better reflecting the majority of dogs with OA.106 This 
is why gait analysis was not used, and an alternative 
objective measure, activity monitoring, was used. 
However, it would be interesting to know how anti-NGF 
therapy compares with NSAIDs using gait analysis 
in dogs, as well as in cats.124–126 Although not yet 
performed, Quantitative Sensory Testing10 11 127 could 
be used to more completely assess sensory function 
changes, as the most common AEs in human use is 
abnormal peripheral sensation.43
While no anti-NGF therapy-related AEs in dogs and 
cats have been seen, the safety of long-term exposure 
over years, possibly starting early in life, needs to 
be determined. Currently, the longest follow-up time 
after anti-NGF mAb therapy in dogs and cats is three 
months, compared with the mean trial duration 
of 199 days in humans. Additionally, the safety 
of concomitant use of NSAIDs with anti-NGF mAb 
therapy has not been elucidated. This will be important 
information because in addition to higher dose and 
longer exposure to anti-NGF mAbs, concurrent use 
of NSAIDs was a risk factor for the development of 
RPOA in the human trials.42 92 Interestingly, RPOA is 
not a recognised or described phenomenon in dogs 
or cats, anecdotally or otherwise. Additionally, the 
normal rates of progression of radiographic OA in 
veterinary species has not been defined, leaving no 
‘benchmark’ against which to evaluate potential cases 
of RPOA. Such a benchmark will be important in order 
to distinguish clinicians’ focus on the progression of 
OA in cases that receive an anti-NGF mAb from true 
RPOA. Currently, there are no data to inform whether 
NSAIDs can be used with anti-NGF mAbs, nor what 
sort of withdrawal period (if any) is needed for NSAIDs 
prior to animals receiving anti-NGF mAbs.
It is likely that if approved, anti-NGF therapy will be 
used in joint diseases of differing aetiopathogenesis, 
and there is much to learn about the role of NGF and 
the effects of anti-NGF in relation to the differing 
pathologies, such as immune-mediated joint disease 
versus non-inflammatory OA.
One final consideration is that if the pain relief 
is indeed greater than seen with NSAIDs, it may be 
prudent to control the increase in activity seen after 
administration of the anti-NGF mAb in order to prevent 
musculoskeletal damage due to overuse of a poorly 
conditioned body. This is speculative but something 
that should be considered as clinical use begins.
Potential use of anti-NGF in other pain conditions
Endogenous levels of NGF are increased in a wide 
range of painful disorders such as inflammatory 
arthritis, degenerative intervertebral disc disease, 
prostatitis and cancer. Administration of anti-NGF 
mAb has been shown to provide effective analgesia 
in a number of animal models of human disease 
including inflammatory arthritis, fracture pain, joint 
surgery, cancer pain and pancreatic pain.71 94 128–130 
Interestingly, in nearly all of conditions, anti-NGF on 
average reduced pain by 30 per cent to 50 per cent and 
this anti-NGF reduction of pain does not appear to 
dissipate with time of treatment.
Cancer pain
An estimated 30  per  cent to 50  per  cent of human 
patients with cancer experience moderate to severe 
cancer-related pain, and in advanced or metastatic 
cancer, 75 per cent to 95 per cent of human patients 
report life-altering cancer induced pain.131 Although 
pain arises from numerous causes, bone metastasis is 
the most common cause of cancer pain. This occurs in 
60 per cent to 84 per cent of patients.132 133 However, 
therapeutics such as opioids, which are commonly 
used in these patients, are not fully effective in many 
patients and often have significant side effects. In 
addition, the use of opioids is contributing to the 
opioid epidemic.134 Thus, in humans, a significant 
unmet need remains for development of novel 
agents for cancer pain treatments. Preclinical and 
clinical research over the past several decades have 
suggested that anti-NGF mAb therapy might have an 
impact on the management of cancer pain.90 135 136 
Almost all sensory innervation of bone is provided by 
nociceptors that express CGRP and TrkA, which are 
susceptible to the blockade by anti-NGF therapy.128 
Additionally, cancers express TrkA and p75NTR and are 
stimulated by NGF, which is thought to contribute to 
cancer progression.137
Rodent models suggest significant therapeutic 
potential in cancer pain in humans, and the same is 
likely true of companion animals. To our knowledge, 
no efficacy studies with anti-NGF mAb have been 
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performed. However, a study showed that the majority 
of canine osteosarcoma primary tumours and 
pulmonary metastases expressed TrkA protein, and its 
signalling protected against apoptosis since blockade 
of NGF/TrkA signalling induced apoptosis of canine 
osteosarcoma cell lines.138 Thus, anti-NGF mAb may 
provide significant relief of bone cancer pain90 and 
slow the progression rate of tumour growth.137
Other orthopaedic pain conditions (fracture and joint 
surgery)
Several rodent studies using hind limb fracture models 
(femur and tibia) in mice demonstrate the analgesic 
potential of anti-NGF therapy. In these models in 
mice, anti-NGF or anti-TrkA mAbs were administered 
intraperitoneally following establishment of the 
fracture, and pain was assessed using observational 
pain behaviour, ground reaction forces, mechanical 
allodynia and recording of locomotor activity. The 
treatment with both anti-NGF and anti-TrkA mAbs 
significantly reduced pain-related behaviour.70 94 95 139 
Furthermore, the efficacy of anti-NGF mAb therapy 
in reducing pain-related behaviours was comparable 
with or greater than that achieved by subcutaneous 
administration of therapeutic dose of morphine.70 In 
these studies, three to four weeks after fracture, bone 
healing was assessed by various techniques such as 
mechanical testing, histomorphometric analysis, 
microcomputed tomography and radiographical 
analysis. They concluded that blockade of NGF/TrkA 
signalling does not influence fracture healing when 
compared with vehicle control group.
In a mouse model of knee joint surgery pain 
(drilling and coring the trochlear groove of the femur), 
pre-emptive intraperitoneal administration of anti-NGF 
mAb significantly attenuated reduction of spontaneous 
activity and frequency of vertical rearing following 
surgery compared with vehicle treated mice.130
Such work suggests potential for the use of anti-NGF 
mAbs for perioperative orthopaedic pain, and such 
therapy would be welcome in veterinary medicine 
where proven analgesic efficacy that can be provided 
following discharge from the clinic is very limited. 
However, much work is needed to define any potential 
side effects related to healing or reinnervation of 
surgical sites.
Visceral pain
Tanezumab has been studied in two proof-of-concept 
trials involving chronic visceral pain in humans.140 
Patients with interstitial cystitis were administered 
a single dose of intravenous tanezumab, a human 
anti-NGF mAb, 200 µg/kg (n=34) or placebo (n=30), 
and assessed over 16 weeks using questionnaires.140 
Tanezumab provided a statistically significant 
reduction in pain scores compared with placebo over 
the first six weeks and reduced urgency frequency. In 
a study evaluating patients with moderate-to-severe 
chronic prostatitis/chronic pelvic pain syndrome, 
30 patients received a single intravenous dose of 
tanezumab (20 mg) and 32 received a placebo.141 They 
were followed over 16 weeks after injection. Although 
average pain score and urgency episode frequency 
trended downwards at a six-week follow-up, neither 
outcome achieved significance. Anti-NGF therapy may 
have potential in visceral pain syndromes; however, 
visceral pain syndromes are not yet well defined in 
companion animals, except for interstitial cystitis in 
cats.
The main symptom of patients with pancreatitis 
is severe abdominal pain. NGF was found to be 
upregulated and notably expressed in the pancreas 
in both human patients with chronic pancreatitis and 
a rat model of acute and chronic pancreatitis.142 143 
Furthermore, in the study of patients with chronic 
pancreatitis, the expression levels of NGF and TrkA 
mRNA in pancreas were strongly related with pain 
intensity and frequency.142 Although, to the best of 
our knowledge, no clinical study has been conducted, 
several studies in acute or chronic pancreatitis 
models in rats showed robust reduction of pain 
following an administration of blockade of NGF/TrkA 
signalling.129 144 145 Anti-NGF therapy may be useful for 
the pain management of acute or chronic pancreatitis 
in companion animals.
Conclusion
Overall, the rationale for using anti-NGF therapy 
in several pain conditions is strong. Current 
evidence indicates that anti-NGF mAb therapy has 
positive analgesic effects and is well tolerated for 
up to three months in dogs and cats suffering from 
OA-associated  pain. Additionally, the efficacy of 
single injection appears to last at least four to six 
weeks and the magnitude of effect appears the same 
as, or greater than, that expected with NSAIDs. Thus, 
anti-NGF mAb therapy could be an alternative to the 
pharmacological pain management options currently 
available. Of particular relevance at the moment is the 
fact that anti-NGF therapy is a non-opioid analgesic. 
Further studies are needed to better understand the 
level of analgesic effect and the duration, and also 
what potential AEs and immunogenicity may occur.
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